JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on...

Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy,...

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a...

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.

The chronic kidney disease market is forecast to grow at a 19.6% CAGR from (Dollar) 2.2 billion in 2023 to (Dollar) 13.5 billion by 2033 across...

Driven by pipeline approvals with diverse mechanisms of action and an influx of newly diagnosed patients, the chronic kidney disease (CKD) market is...

The CAPItello─290 phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or...

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's...

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy